In 2008 Novozymes’ stock price performed better than most benchmark indexes. The stock price was, however, subject to high volatility throughout the year.
Novozymes’ stock price developed below market average at the beginning of the year. However, delivering strong results during a deepening global financial crisis improved Novozymes’ stock performance compared to market average in the later part of the year.
Novozymes’ overall financial ambition is to provide its shareholders with competitive returns. Shareholder value is created by stock price appreciation, dividend payments, and stock buy-backs.
The Novozymes stock is listed on NASDAQ OMX Copenhagen A/S and included in the OMX Copenhagen 20 index (OMXC20). The stock is listed under ticker code NZYM B and ISIN DK0010272129.